notice. malathion revised risk assessments notice of availability and solicitation of risk reduction options available in english 9 pages this notice announces the availability of epas revised human health risk assessment and as well as the start of a 60-day comment period ecological risk assessment for the organophosphate pesticide malathion. a revised human health assessment on malathion was conducted to incorporate toxicity data which epa received after 2000. since no additional ecological data on malathion has been received after 2000 epas ecological risk characterization has remained unchanged. this notice also solicits information or data from stakeholders and interested parties to hel refine the malathion risk assessment and encourages parties to suggest risk management ideas or proposals to address the potential risks which have been identified. epa is developing an interim reregistration eligibility decision ired for malathion through the full 6-phase public participation process which in this case includes reissuing the revised risk assessment for an additional phase 5 public comment period. the agency uses this process to involve the public in developing pesticide reregistration and tolerance reassessment decisions. through these programs epa is ensuring that all pesticides meet current health and safety. malathion is characterized as a non-systemic broad spectrum organophosphate pesticide with numerous commercial agricultural uses residential uses and as well as several wide area uses. malathions wide area applications include use as a public health mosquitocide use to control fruit flies and use in eradication programs such as the us department of argricultures boll weevil eradication program. malathion is also formulated into a pharmaceutical product ovide lotion which is approved by the food and drug administration for the control of head lice and their ova. epas revised human health risk assessment has identified potential risks of concern from various uses of malathion some of which are derived mainly from potential exposure to malathions oxygen metabolite malaoxon. concerns include potential exposure to malaoxon through drinking water and from drift as a result of wide area applications. the agency also has potential risk concerns for adults and children who may be exposed to malathion per se from the home fogger use of malathion. epa has also included an analysis of the pharmaceutical use of malathion. the analysis of the pharmaceutical use presents the proposed safety findings on malathion as a pharmaceutical and a pesticide product from the joint perspective of both the food and drug administration and epa